Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and …

M Perera, N Papa, M Roberts, M Williams, C Udovicich… - European urology, 2020 - Elsevier
Context Accurate staging of high-risk localised, advanced, and metastatic prostate cancer is
becoming increasingly more important in guiding local and systemic treatment. Gallium-68 …

[HTML][HTML] PSMA PET/CT for primary staging of prostate cancer-an updated overview

MR Jochumsen, K Bouchelouche - Seminars in Nuclear Medicine, 2024 - Elsevier
Prostate-specific membrane antigen PET/CT for primary staging of prostate cancer is
becoming increasingly popular due to simultaneous assessment of whole-body disease …

Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of …

I Sonni, ER Felker, AT Lenis, AE Sisk… - Journal of Nuclear …, 2022 - Soc Nuclear Med
The role of prostate-specific membrane antigen (PSMA)–targeted PET in comparison to
multiparametric MRI (mpMRI) in the evaluation of intraprostatic cancer foci is not well …

PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy

W Jones, K Griffiths, PC Barata, CJ Paller - Cancers, 2020 - mdpi.com
Prostate-specific membrane antigen (PSMA) has been the subject of extensive investigation
in the past two decades as a promising molecular target for prostate cancer (PCa). Its …

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer …

HB Luiting, PJ van Leeuwen, MB Busstra… - BJU …, 2020 - Wiley Online Library
Objectives To review the literature to determine the sensitivity and specificity of gallium‐68
prostate‐specific membrane antigen (68Ga‐PSMA) positron‐emission tomography (PET) for …

A prospective study on 18F-DCFPyL PSMA PET/CT imaging in biochemical recurrence of prostate cancer

E Rousseau, D Wilson, F Lacroix-Poisson… - Journal of Nuclear …, 2019 - Soc Nuclear Med
18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-
pentanedioic acid), a prostate-specific membrane antigen–targeting radiotracer, has shown …

[HTML][HTML] Bone metastasis in prostate cancer: bone scan versus PET imaging

N Mohseninia, N Zamani-Siahkali, S Harsini… - Seminars in Nuclear …, 2024 - Elsevier
Prostate cancer is the second most common cause of malignancy among men, with bone
metastasis being a significant source of morbidity and mortality in advanced cases …

Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically …

HD Zacho, JB Nielsen, A Afshar-Oromieh… - European Journal of …, 2018 - Springer
Purpose To prospectively compare diagnostic accuracies for detection of bone metastases
by 68 Ga-PSMA PET/CT, 18 F-NaF PET/CT and diffusion-weighted MRI (DW 600-MRI) in …

Quantitative bone SPECT/CT: high specificity for identification of prostate cancer bone metastases

F Tabotta, M Jreige, N Schaefer, F Becce… - BMC musculoskeletal …, 2019 - Springer
Purpose Bone scintigraphy with 99m Tc-labeled diphosphonates can identify prostate
cancer bone metastases with high sensitivity, but relatively low specificity, because benign …

Head-To-Head Comparison of 68Ga-PSMA-11 PET/CT and 99mTc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A …

G Zhao, B Ji - American Journal of Roentgenology, 2022 - Am Roentgen Ray Soc
Please see the Editorial Comment by Sungmin Woo discussing this article. BACKGROUND.
Bone scintigraphy (BS) using 99mTc-labeled methylene diphospho-nate (99mTc-MDP) …